Literature DB >> 7660446

Treatment of kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days.

R Dietze1, S M Fagundes, E F Brito, E P Milan, T F Feitosa, F A Suassuna, G Fonschiffrey, G Ksionski, J Dember.   

Abstract

We have treated 10 patients suffering from kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) at a dose of 2 mg/kg/d for 5 d, following an earlier study in which this dosage for 7 d was found to cure all of 9 patients, with no relapse during 12 months. In the present study, all patients demonstrated initial resolution of disease. Parasites were absent upon bone marrow re-aspiration 2 weeks after therapy; no spleen extended beyond the costal margin 2 months after therapy; white blood cell counts, platelet counts, and serum levels of albumin rapidly returned to normal. Although one patient relapsed at 5 months, 8 of the other 9 patients had spleens of normal size (undetectable on deep palpation) at 12 months after therapy. Fever, sometimes accompanied by increased respiratory rate, occurred on the first day of drug infusion in 8 of 10 patients and was more severe in patients < 6 years old. Pre-medication with a non-steroidal anti-inflammatory agent (diclofenac potassium) before the next 4 infusions protected against this side effect in 5 of 6 patients. The results of this and our previous study suggest that the most appropriate regimen of Amphocil for kala-azar is 2 mg/kg/d for 7 d, with pre-medication each day, in patients aged > 5 years.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7660446     DOI: 10.1016/0035-9203(95)90557-x

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  12 in total

Review 1.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  Sequential treatment of deep fungal infections with amphotericin B deoxycholate and amphotericin B colloidal dispersion.

Authors:  B Beović; T Lejko-Zupanc; J Pretnar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-07       Impact factor: 3.267

3.  In search of the amazing technicolour dream coat for amphotericin B.

Authors:  J Conly; S Shafran
Journal:  Can J Infect Dis       Date:  1996-07

4.  Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis.

Authors:  V Yardley; S L Croft
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

5.  Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome.

Authors:  J P Gangneux; A Sulahian; Y J Garin; R Farinotti; F Derouin
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

6.  Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial.

Authors:  S Sundar; G Agrawal; M Rai; M K Makharia; H W Murray
Journal:  BMJ       Date:  2001-08-25

7.  Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in BALB/c mice.

Authors:  Y Le Fichoux; D Rousseau; B Ferrua; S Ruette; A Lelièvre; D Grousson; J Kubar
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

8.  Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis.

Authors:  A B Mullen; K C Carter; A J Baillie
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

Review 9.  Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.

Authors:  R N Brogden; K L Goa; A J Coukell
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

Review 10.  Control of visceral leishmaniasis in latin america-a systematic review.

Authors:  Gustavo A S Romero; Marleen Boelaert
Journal:  PLoS Negl Trop Dis       Date:  2010-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.